{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T21:59:30Z","timestamp":1777067970478,"version":"3.51.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T00:00:00Z","timestamp":1481932800000},"content-version":"vor","delay-in-days":54,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"DOI":"10.1093\/jjco\/hyw103","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T01:23:27Z","timestamp":1472520207000},"page":"1031-1041","source":"Crossref","is-referenced-by-count":22,"title":["Key predictive factors for efficacy of axitinib in first-line\n                    metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a\n                    randomized, double-blind phase II study"],"prefix":"10.1093","volume":"46","author":[{"given":"Yoshihiko","family":"Tomita","sequence":"first","affiliation":[{"name":"Department of Urology,\n                    Yamagata University Faculty of Medicine,\n                    Yamagata"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Fukasawa","sequence":"additional","affiliation":[{"name":"Prostate Center and Division of\n                    Urology, Chiba Cancer Center,\n                    Chiba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[{"name":"Department of Urology,\n                    Keio University School of Medicine,\n                    Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Urology,\n                    Kinki University School of Medicine,\n                    Osaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Department of Urology,\n                    Hokkaido University Graduate School of Medicine,\n                    Hokkaido"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[{"name":"Department of Urology,\n                    Akita University School of Medicine,\n                    Akita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[{"name":"Department of Solid Tumor\n                    Oncology, Cleveland Clinic Taussig Cancer\n                    Institute, Cleveland,\n                    OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Pfizer Oncology,\n                    San Diego, CA,\n                    USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel H.","family":"Bair","sequence":"additional","affiliation":[{"name":"Pfizer Oncology,\n                    San Diego, CA,\n                    USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Ozono","sequence":"additional","affiliation":[{"name":"Department of Urology,\n                    Hamamatsu University School of Medicine,\n                    Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Urology,\n                    Kyushu University, Graduate School of\n                    Medical Sciences, Fukuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Akaza","sequence":"additional","affiliation":[{"name":"Strategic Investigation on\n                    Comprehensive Cancer Network, Interfaculty Initiative in\n                    Information Studies\/Graduate School of Interdisciplinary Information\n                    Studies, The University of Tokyo,\n                    Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"key\n\t\t\t\t2018111910323406900_hyw103C1","first-page":"7272","article-title":"Nonclinical antiangiogenesis and\n                        antitumor activities of axitinib (AG-013736), an oral, potent, and selective\n                        inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1,\n                        2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C2","first-page":"1931","article-title":"Comparative effectiveness of\n                        axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a\n                        randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C3","first-page":"5474","article-title":"Phase I trial of the oral\n                        antiangiogenesis agent AG-013736 in patients with advanced solid tumors:\n                        pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin\n                        Oncol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C4","first-page":"491","article-title":"Axitinib in metastatic renal cell\n                        carcinoma: results of a pharmacokinetic and pharmacodynamic\n                        analysis","volume":"53","author":"Rini","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C5","first-page":"1233","article-title":"Axitinib with or without dose\n                        titration for first-line metastatic renal-cell carcinoma: a randomised\n                        double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C6","first-page":"2592","article-title":"Key predictive factors of axitinib\n                        (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese\n                        patients with cytokine-refractory metastatic renal cell\n                        Carcinoma","volume":"47","author":"Tomita","year":"2011","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C7","first-page":"616","article-title":"Efficacy and safety of axitinib\n                        versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of\n                        Japanese patients from the global randomized Phase 3 AXIS\n                        trial","volume":"43","author":"Ueda","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C8","first-page":"563","article-title":"Effect of rifampin on the\n                        pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy\n                        volunteers","volume":"65","author":"Pithavala","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C9","first-page":"963","article-title":"Effect of axitinib (AG-013736) on\n                        fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in\n                        Japanese patients","volume":"101","author":"Mukohara","year":"2010","journal-title":"Cancer Sci"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C10","first-page":"1055","article-title":"Management of axitinib\n                        (AG-013736)-induced fatigue and thyroid dysfunction, and predictive\n                        biomarkers of axitinib exposure: results from phase I studies in Japanese\n                        patients","volume":"30","author":"Fujiwara","year":"2012","journal-title":"Invest New Drugs"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C11","first-page":"866","article-title":"Phase I\/II study of sunitinib\n                        malate in Japanese patients with gastrointestinal stromal tumor after\n                        failure of prior treatment with imatinib mesylate","volume":"28","author":"Shirao","year":"2010","journal-title":"Invest New Drugs"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C12","first-page":"1492","article-title":"Phase I and pharmacokinetic study\n                        of sorafenib, an oral multikinase inhibitor, in Japanese patients with\n                        advanced refractory solid tumors","volume":"99","author":"Minami","year":"2008","journal-title":"Cancer\n                        Sci"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C13","first-page":"673","article-title":"Phase 1 study of pazopanib alone or\n                        combined with lapatinib in Japanese patients with solid\n                        tumors","volume":"73","author":"Inada-Inoue","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C14","first-page":"1166","article-title":"Overall survival and updated\n                        results from a phase II study of sunitinib in Japanese patients with\n                        metastatic renal cell carcinoma","volume":"40","author":"Tomita","year":"2010","journal-title":"Jpn J Clin\n                        Oncol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C15","first-page":"755","article-title":"Phase II study to investigate the efficacy, safety, and\n                        pharmacokinetics of sorafenib in Japanese patients with advanced renal cell\n                        carcinoma","volume":"37","author":"Akaza","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C16","first-page":"2103","article-title":"Bevacizumab plus interferon alfa-2a\n                        for treatment of metastatic renal cell carcinoma: a randomised, double-blind\n                        phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C17","first-page":"5422","article-title":"Bevacizumab plus interferon alfa\n                        compared with interferon alfa monotherapy in patients with metastatic renal\n                        cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C18","first-page":"125","article-title":"Sorafenib in advanced clear-cell\n                        renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C19","first-page":"1061","article-title":"Pazopanib in locally advanced or\n                        metastatic renal cell carcinoma: results of a randomized phase III\n                        trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C20","first-page":"115","article-title":"Sunitinib versus interferon alfa in\n                        metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J\n                        Med"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C21","first-page":"1287","article-title":"Axitinib versus sorafenib as\n                        first-line therapy in patients with metastatic renal-cell carcinoma: a\n                        randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet\n                        Oncol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C22","first-page":"194","article-title":"A phase II study of sunitinib in\n                        Japanese patients with metastatic renal cell carcinoma: insights into the\n                        treatment, efficacy and safety","volume":"40","author":"Uemura","year":"2010","journal-title":"Jpn J Clin\n                        Oncol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C23","first-page":"67","article-title":"Treatment outcomes of sunitinib\n                        treatment in advanced renal cell carcinoma patients: a single cancer center\n                        experience in Korea","volume":"41","author":"Hong","year":"2009","journal-title":"Cancer Res Treat"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C24","first-page":"249","article-title":"Efficacy of sorafenib on metastatic\n                        renal cell carcinoma in Asian patients: results from a multicenter\n                        study","volume":"9","author":"Zhang","year":"2009","journal-title":"BMC Cancer"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C25","first-page":"450","article-title":"Efficacy and safety of sunitinib on metastatic renal cell\n                        carcinoma: a single-institution experience","volume":"51","author":"Hwang","year":"2010","journal-title":"Korean J\n                        Urol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C26","first-page":"980","article-title":"The efficacy and safety of\n                        sunitinib in korean patients with advanced renal cell carcinoma: high\n                        incidence of toxicity leads to frequent dose reduction","volume":"40","author":"Yoo","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C27","first-page":"310","article-title":"Risk factors for sorafenib-induced\n                        high-grade skin rash in Japanese patients with advanced renal cell\n                        carcinoma","volume":"24","author":"Tsuchiya","year":"2013","journal-title":"Anticancer Drugs"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C28","first-page":"825","article-title":"Pharmacogenetic determinants\n                        associated with sunitinib-induced toxicity and ethnic difference in Korean\n                        metastatic renal cell carcinoma patients","volume":"72","author":"Kim","year":"2013","journal-title":"Cancer\n                        Chemother Pharmacol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C29","first-page":"552","article-title":"Axitinib versus sorafenib as\n                        second-line treatment for advanced renal cell carcinoma: overall survival\n                        analysis and updated results from a randomised phase 3\n                    trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C30","first-page":"2470","article-title":"Prognostic factors for survival in\n                        1059 patients treated with sunitinib for metastatic renal cell\n                        carcinoma","volume":"108","author":"Motzer","year":"2013","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t2018111910323406900_hyw103C31","first-page":"5794","article-title":"Prognostic factors for overall\n                        survival in patients with metastatic renal cell carcinoma treated with\n                        vascular endothelial growth factor-targeted agents: results from a large,\n                        multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/46\/11\/1031\/26649807\/hyw103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T15:48:16Z","timestamp":1542642496000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/46\/11\/1031\/2445892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,10,24]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyw103","relation":{},"ISSN":["1465-3621","0368-2811"],"issn-type":[{"value":"1465-3621","type":"electronic"},{"value":"0368-2811","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,11]]},"published":{"date-parts":[[2016,10,24]]}}}